Risperidone: Truly Non-Cataleptogenic?
Notice bibliographique
Résumé
ABSTRACT Although risperidone has been hailed as a 'truly non-cataleptogenic' antipsychotic and endorsed in standard textbooks as a drug causing minimal or negligible extrapyramidal symptoms at therapeutic doses, our clinical experience with this drug suggests otherwise and prompted this retrospective chart-review of 43 patients receiving risperidone 2-10 mg/day (both median and modal dose: 6 mg/day) for at least 1 month. While taking a mean dose of 5.77 mg/day, which is well within the therapeutic dose range, 29 patients (67%) developed documented extrapyramidal symptoms, mostly parkinsonism but also akathisia and others. Most patients developed extrapyramidal symptoms in the dose range of 5-7 mg/day (17 of 26, 61.5%), although symptoms were also seen in 9 patients receiving a dose of 2-4 mg/day. That the extrapyramidal symptoms were often clinically significant can be gauged from the fact that 83% of those developing extrapyramidal symptoms required institution of an anticholinergic drug, and 31% required a mean risperidone dose reduction of 2 mg/day. Extrapyramidal symptoms had to be managed by risperidone discontinuation (7% of patients) or a combination of an anticholinergic plus risperidone dose reduction (7%). These observations, though of a retrospective and uncontrolled nature, appear too obvious to be ignored and reflect a need for further study into this issue using a prospective, double-blind, randomised, controlled trial. Key words: Extrapyramidal Symptoms; Retrospective Study; Risperidone; Side Effects INTRODUCTION Risperidone, a serotonergic-dopaminergic antagonist, has been hailed as a 'truly non-cataleptogenic' antipsychotic, (1) meaning that it does not produce extrapyramidal symptoms (EPS). The general consensus regarding risperidone is that it certainly causes fewer EPS than other, 'typical' neuroleptics and that any EPS seen in the context of therapeutic dose ranges of risperidone are usually mild. (2) This view has been broadly endorsed by standard textbooks and research literature alike. (2-9) In a USA-Canada multicentre project, Marder et al. (3) and Marder and Meibach, (4) reported EPS with risperidone in daily doses of up to 16 mg to be no more common than in the placebo groups. Cunningham suggested no significant difference in EPS reported by patients receiving doses [less than or equal to] 10 mg from the placebo group. (5) Within the recommended therapeutic range (4-8 mg), the incidence and severity of EPS are reported to be much less than 20 mg of haloperidol, even up to 12 months, making risperidone a safer and better tolerated drug than the conventional neuroleptics. Incidence of parkinsonism is reported to be negligible in the therapeutic dose range. (6) Indeed, risperidone has also been shown to decrease pre-existing tremors and rigidity. (1,7) From these observations one would conclude that risperidone has a safe EPS profile. (8,9) Our day-to-day clinical experience with risperidone, however, suggests otherwise. A sizeable proportion of patients with schizophrenia or other psychotic disorders taking risperidone began to show EPS that were clinically obvious, often necessitating a halt in further dose increases, reduction of dose, or addition of anticholinergic agents such as trihexyphenidyl. This observation prompted us to review the situation by a chart-review study. Thus, this study had the following objectives: * To ascertain the proportion of patients receiving risperidone who develop EPS. * To study the characteristics of EPS and their relation to dose and duration of risperidone therapy. * To determine the clinical significance of EPS in this group as judged by necessity of risperidone dose reduction and/ or anticholinergic supplementation. * To examine any differences between those patients taking risperidone who developed EPS and those who did not. MATERIALS AND METHODS The study was conducted at the Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India. …
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,003 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».